Delayed Injection Site Reaction After mRNA-1273 Vaccination in Japan: A Retrospective, Cross-Sectional Study

Masaya Hibino; Takuma Ishihara; Mitsunaga Iwata; Yohei Doi

doi:10.1093/ofid/ofab497

Delayed Injection Site Reaction After mRNA-1273 Vaccination in Japan: A Retrospective, Cross-Sectional Study

Open Forum Infect Dis. 2021 Oct 3;8(10):ofab497. doi: 10.1093/ofid/ofab497. eCollection 2021 Oct.

Authors

Masaya Hibino¹, Takuma Ishihara², Mitsunaga Iwata¹, Yohei Doi^{3

4

5}

Affiliations

¹ Department of Emergency and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
² Innovative and Clinical Research Promotion Center, Gifu University Hospital, Yanagido, Gifu, Japan.
³ Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
⁴ Department of Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
⁵ Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Abstract

The incidence of delayed injection site reaction after the first dose of mRNA-1273 vaccine was 12.5% among females and 1.5% among males in a cohort of primarily elderly Japanese. After the second dose, 48.4% of those who could be contacted reported recurrence. The reaction may be relatively common among Asian females.

Keywords: COVID arm; COVID-19; Moderna arm; delayed hypersensitivity; mRNA.